Literature DB >> 27249718

Arming the Immune System Through Vaccination to Prevent Cancer Recurrence.

Diane F Hale1, Timothy J Vreeland1, George E Peoples1.   

Abstract

Cancer vaccines have the potential to provide a nontoxic treatment for the prevention of cancer recurrence in the adjuvant setting. Many cancer vaccines have been tested in multiple phase III trials with minimal success. However, through these failed clinical trials, we have learned that the ideal setting for vaccine therapy is the adjuvant setting. Also, we have learned important lessons about patient selection to maximize the probability of success. This article will highlight some of the successes, our trial results in the adjuvant setting, and future directions.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27249718     DOI: 10.1200/EDBK_158946

Source DB:  PubMed          Journal:  Am Soc Clin Oncol Educ Book        ISSN: 1548-8748


  6 in total

1.  Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.

Authors:  Timothy J Vreeland; Jennifer K Litton; Na Qiao; Anne V Philips; Gheath Alatrash; Diane F Hale; Doreen O Jackson; Kaitlin M Peace; Julia M Greene; John S Berry; Guy T Clifton; George E Peoples; Elizabeth A Mittendorf
Journal:  Clin Immunol       Date:  2018-03-21       Impact factor: 3.969

Review 2.  Human Tumor Antigens Yesterday, Today, and Tomorrow.

Authors:  Olivera J Finn
Journal:  Cancer Immunol Res       Date:  2017-05       Impact factor: 11.151

3.  Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.

Authors:  Robert C Chick; Mark B Faries; Diane F Hale; Phillip M Kemp Bohan; Annelies T Hickerson; Timothy J Vreeland; John W Myers; Jessica L Cindass; Tommy A Brown; John Hyngstrom; Adam C Berger; James W Jakub; Jeffrey J Sussman; Montaser Shaheen; Guy T Clifton; Hyohyun Park; Amanda J Sloan; Thomas Wagner; George E Peoples
Journal:  Cancer Med       Date:  2021-05-12       Impact factor: 4.452

4.  Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.

Authors:  Tommy A Brown; Kevin Byrd; Timothy J Vreeland; Guy T Clifton; Doreen O Jackson; Diane F Hale; Garth S Herbert; John W Myers; Julia M Greene; John S Berry; Jonathan Martin; John C Elkas; Thomas P Conrads; Kathleen M Darcy; Chad A Hamilton; George L Maxwel; George E Peoples
Journal:  Cancer Med       Date:  2019-07-05       Impact factor: 4.452

Review 5.  Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade.

Authors:  Alice Mougel; Magali Terme; Corinne Tanchot
Journal:  Front Immunol       Date:  2019-03-14       Impact factor: 7.561

6.  Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model.

Authors:  Dina Stroopinsky; Jessica Liegel; Manoj Bhasin; Giulia Cheloni; Beena Thomas; Swati Bhasin; Ruchit Panchal; Haider Ghiasuddin; Maryam Rahimian; Myrna Nahas; Shira Orr; Marzia Capelletti; Daniela Torres; Cansu Tacettin; Matthew Weinstock; Lina Bisharat; Adam Morin; Kathleen M Mahoney; Benjamin Ebert; Richard Stone; Donald Kufe; Gordon J Freeman; Jacalyn Rosenblatt; David Avigan
Journal:  Haematologica       Date:  2021-05-01       Impact factor: 9.941

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.